GLP-1 Drugs Reduce Liver Enzyme ALT and BMI in Youth with Obesity: Meta-Analysis | Research

The takeaway

Meta-analysis of 6 RCTs found GLP-1 RAs significantly reduced BMI (-1.7, p=0.02) and ALT (-3.0, p=0.01) in youth with obesity, but showed no significant effect on other metabolic parameters.

ALT drops too
GLP-1 drugs reduced the liver enzyme ALT significantly in obese youth (p=0.01), suggesting liver protection beyond weight loss alone

What the researchers found

GLP-1 RAs in youth: BMI -1.7 (p=0.02), ALT -3.0 (p=0.01). No significant changes in HDL, LDL, or HbA1c. 6 RCTs included (4 exenatide, 1 semaglutide, 1 liraglutide).

Why it matters

Pediatric fatty liver disease is epidemic. Finding that GLP-1 drugs reduce ALT in children suggests liver protection beyond weight loss.

How the study worked

Systematic review and meta-analysis of PubMed, Scopus, and Embase for RCTs of GLP-1 RAs in youth with obesity, 6 studies included (11-201 participants, 12-68 weeks).

What this study cannot tell us

Small number of studies (6). Heterogeneous agents (mostly exenatide). ALT reduction clinical significance uncertain. Short durations.

How to read the evidence

Meta-analysis of 6 RCTs. Limited by small, heterogeneous studies. BMI and ALT findings robust.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs may protect young livers from obesity-related damage, adding to the rationale for earlier pediatric use.

Questions still open

Would longer GLP-1 treatment produce significant lipid improvements in youth?
Is the ALT reduction clinically meaningful for preventing NAFLD progression?
Should ALT monitoring guide GLP-1 therapy decisions in obese children?

Common questions

Do GLP-1 drugs help children's livers?

This meta-analysis found GLP-1 drugs significantly reduced ALT (a liver damage marker) in obese children, suggesting they may protect developing livers from obesity-related fatty liver disease.

Why don't other metabolic markers improve?

The studies were relatively short (12-68 weeks) and mostly used older GLP-1 drugs (exenatide). Longer treatment with newer agents like semaglutide may show improvements in cholesterol and blood sugar.

Read the original research

The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.

Childhood obesity (Print), 22(2), 100-104

View on PubMed ↗Publisher’s paper ↗

Citation

Hertzer, Lauren A; Siegel, Robert M; Kharofa, Roohi Y; Stackpole, Kristin M; Mahabee-Gittens, E Melinda. (2026). The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.. Childhood obesity (Print), 22(2), 100-104. https://doi.org/10.1177/21532176251413898